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LETTER TO THE EDITOR
Comment on: ‘‘Cytotoxicity of Oxycodone and Morphine
in Human Neuroblastoma and Mouse Motoneuronal Cells:
A Comparative Approach’’
Richard B. Parsons1
 The Author(s) 2016. This article is published with open access at Springerlink.com
One of the most controversial aspects of in vitro drug
toxicity testing is the choice of cell model. This is espe-
cially true of neurotoxicity testing, where faithful repro-
duction of the in vivo phenotype is critical for accurate and
relevant interpretation of drug toxicity, in particular in
relation to clinically relevant compounds. Cell line models
are attractive because of their ease of use, their high
reproducibility, the high volume of homogeneous cells that
can be obtained, and the low cost. In this issue, Kokki et al.
[1] have used the SH-SY5Y and NSC-34 cell lines to assess
the toxicity of oxycodone, the most commonly used opioid
for the treatment of moderate to severe back pain, and
compared it to that of morphine, using two standard toxi-
city assays, 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) and resazurin reduction assays.
They report that the toxicity profiles of both compounds are
similar, and that the toxicity of oxycodone only occurs at
concentrations above the peak clinical concentration in the
cerebrospinal fluid after intrathecal administration [1].
Although a well-executed and important study, in order
to make conclusions about clinically relevant compounds
that will be of relevance to clinicians, one must ensure that
the cell model used is as clinically relevant as possible. By
their very nature, in vitro cell models do not closely
replicate in vivo phenotypes. Instead, all one can strive for
is to use a cell model that mimics as closely as possible the
in vivo phenotype. Advances in primary neurone and stem
cell cultures have brought the reality of a clinically relevant
neuronal cell model closer, yet they are still not suitable for
the majority of neurotoxicity studies published in the lit-
erature. As such, the majority of neurotoxicity studies use
cell lines as a cell model, with two different cell lines
commonly used to demonstrate that any effects observed
do not arise from a lack of congruency with the in vivo
phenotype, as was done by Kokki and colleagues. But in
order for this to be a valid approach, one must use the most
clinically relevant cell lines available. This is even more
imperative when the cell lines used in a study can easily be
made more clinically relevant. The two models chosen and
as used by the authors are limited in their clinical relevance
as they have not been differentiated prior to neurotoxicity
testing. Although widely used in neurotoxicity research,
the suitability of SH-SY5Y for neurotoxicity studies is
controversial [2]. Although they do demonstrate neuronal
characteristics such as the expression of the synaptic
marker synaptophysin and their ability to accumulate and
release dopamine upon potassium challenge [3], SH-SY5Y
cells are a tumour-derived pan-neuronal cell line whose
culture conditions can have a significant effect upon their
toxic response [4]. Also, one must question whether such
neurones would be exposed in vivo to oxycodone by
intrathecal administration. The use of NSC-34 cells is a
more logical choice; NSC-34 is a motor neurone-like
hybrid cell line produced by the fusion of neuroblastoma
with mouse motorneuron-enriched primary spinal cord
cells [5, 6]. These cells demonstrate neuronal features such
as voltage-gated ion channels, axonal transport and choline
acetyltransferase activity, and more closely resemble the
type of neurone one would expect to be exposed to oxy-
codone via intrathecal administration. However, like SH-
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SY5Y, in their undifferentiated state, they possess a tumour
rather than a neuronal phenotype [3, 7, 8].
The use of undifferentiated cells can be desirable; for
example, we have used undifferentiated SH-SY5Y cells in
our studies to investigate the effects of nicotinamide N-
methyltransferase expression upon neuron morphology,
biochemistry and neurotoxin susceptibility [3, 9–11],
effects that would not have been possible using differen-
tiated SH-SY5Y [12]. However, for the study of Kokki and
colleagues, differentiated cells, which have a neuronal
rather than tumour phenotype [7, 8], are more clinically
relevant than undifferentiated cells and thus would produce
more clinically relevant results. Differentiation is easily
achieved using a combination of reduction of media serum
concentration and supplementation with retinoic acid,
producing cells with a terminally differentiated neuronal
phenotype as evidenced by increased expression of neu-
ronal markers such as NeuN, and a neuronal morphology as
evidenced by the production of neurites [7, 8]. Although
there is significant discussion in the literature regarding the
degree of differentiation afforded by retinoic acid-based
protocols, it is clear that retinoic acid treatment results in
the differentation of SH-SY5Y and NSC-34 into pheno-
types that are closer to the in vivo neuronal phenotype and
as such are a more clinically relevant cell model. The
consequence of using these more clinically relevant models
is that the relative toxicity profiles and 50 % lethal dose
(LD50) values of both oxycodone and morphine are likely
to be significantly different to those reported in Kokki
et al.’s study. For example, compared with undifferentiated
cells, differentiated SH-SY5Y cells demonstrate increased
sensitivity towards 6-hydroxydopamine [7] and rotenone
[13], with decreased sensitivity towards lactacystin [13]
and 1-methyl-4-phenyltetrahydropyridinium ion [14],
whereas NSC-34 demonstrate reduced sensitivity towards
H2O2, tumour necrosis factor-a and glutamate upon dif-
ferentiation [6]. Hence, if you are trying to make clinically
relevant conclusions about clinically relevant compounds,
you must use the most clinically relevant model available,
especially when the production of such a model from cells
already being used is relatively simple.
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